Physician profile
Surrender Raina
NPI 1184662165
$11,111.22
in general payments reported to CMS, 2019-2025
37 companies · $4,161 in 2025
The $4,161 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $601 · 2020: $345 · 2021: $707 · 2022: $1,028 · 2023: $1,635 · 2024: $2,635 · 2025: $4,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,211 · Travel and Lodging: $3,151 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,210.52 |
| Travel and Lodging | $3,151.14 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,434.65 | 2021-2025 | Hawkone, Mo.Ma Ultra, Symplicity G3 |
| Shockwave Medical, INC | $1,709.93 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Becton, Dickinson and Company | $1,019.52 | 2024-2025 | Lutonix Drug Coated Balloon, Ultraverse 014, Rotarexs 6 F X 135 Cm |
| E.R. Squibb & Sons, L.L.C. | $552.38 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $398.06 | 2022-2025 | Ranger, Eluvia, Rubicon 18 |
| Janssen Pharmaceuticals, INC | $346.88 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $341.84 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $310.85 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Pfizer INC. | $235.68 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $228.28 | 2020-2025 | Opsumit, Opsynvi, Uptravi |
| Bard Peripheral Vascular, INC. | $222.68 | 2019-2025 | Rotarexs 6 F X 135 Cm |
| Sanofi-Aventis U.S. LLC | $176.45 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $155.19 | 2019-2024 | Brilinta, Farxiga |
| Atricure, INC. | $145.82 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $105.04 | 2021-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surrender Raina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.